Skip to main content

Home/ Groups/ OARS funding Cancer
MiamiOH OARS

Emerging Leader Award | The Mark Foundation for Cancer Research - 0 views

  •  
    The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.
MiamiOH OARS

Metastasis Research Network (U54 Clinical Trial Not Allowed) - 0 views

  •  
    The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states.
MiamiOH OARS

DoD Kidney Cancer, Concept Award - 0 views

  •  
    The FY20 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. A Congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations Also listed under: -Translational Research Partnership Award -Early-Career Investigator Award
MiamiOH OARS

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent C... - 0 views

  •  
    The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
MiamiOH OARS

NETRF Research Funding Opportunities - 0 views

  •  
    To that end, the foundation is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: Accelerator Award - Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. Investigator Awards - Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Pilot Awards - Grants of up to $100,000 over one year will be awarded for pilot studies. Mentored Awards - Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.
MiamiOH OARS

Grant Application - When Everyone Survives - 0 views

  •  
    To that end, the foundation is accepting proposals for innovative leukemia research. Grants of up to $50,000 over a year will be awarded to new and established investigators for lab, translational, or clinical research related to acute leukemia. Renewals of initial research support may be considered for one or more additional years based on productivity.
MiamiOH OARS

Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial ... - 0 views

  •  
    The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.
MiamiOH OARS

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not All... - 0 views

  •  
    The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
MiamiOH OARS

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) - 0 views

  •  
    The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).
MiamiOH OARS

AACR-Bayer Fellowships | American Association for Cancer Research - 0 views

  •  
    The AACR-Bayer Stimulating Therapeutic Advances through Research Training (START) Grants represent an exciting initiative to encourage and support collaboration between academia and industry. This novel model provides support for three years to postdoctoral and clinical research fellows working on a mentored cancer research project and includes one year spent on site at a Bayer facility. The combined academic and industry training provided through this program will be invaluable to young investigators, allowing them to attain a comprehensive research experience. Projects must have direct applicability and relevance to clinical translation and development in solid tumors and hematologic malignancies.
MiamiOH OARS

DoD, Breast Cancer, Breakthrough Award Level 3 - 0 views

  •  
    Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The current Program Announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other Program Announcements (W81XWH-20-BCRP- BTA12-2 for Levels 1 and 2 and W81XWH-20-BCRP-BTA4-2 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award Program Announcements before submitting the pre- application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.
MiamiOH OARS

DoD, Breast Cancer, Breakthrough Award Level 4 - 0 views

  •  
    Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget.
MiamiOH OARS

DoD Melanoma, Translational Research Award - 0 views

  •  
    The FY20 MRP Translational Research Award (TRA) supports hypothesis-driven, translational, high-impact research. The TRA mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical melanoma issues, which, if successfully addressed, have the potential to make a major impact. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples from clinical trials and/or biorepositories. The TRA supports identifying scientific outcomes, through rigorous, robust research, that are translatable toward treatment and/or preventive strategies. Proposed research should be mature and well developed. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. The TRA is not intended to study research into clinical utility of PD-1 in combination with other therapeutics, or studies utilizing established cell lines. Variety of DOD Melanoma research grants
MiamiOH OARS

New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Cli... - 0 views

  •  
    The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.
MiamiOH OARS

NOT-CA-20-045: Notice of Special Interest (NOSI): Advancing Cancer Data Repositories an... - 0 views

  •  
    The purpose of this Notice is to inform potential applicants of the special interest of the National Cancer Institute (NCI) in encouraging the submission of applications to either PAR-20-089 Biomedical Data Repository ( U24-Clinical Trial Not Allowed) or PAR-20-097 Biomedical Knowledgebase ( U24-Clinical Trial Not Allowed) FOAs, focused on the establishment of new, or continued development of established cancer data resources that use state-of-the-art and cost-effective technologies and approaches, and that are of high value to the broad cancer research community. This NOSI applies to applications for both data repositories and knowledgebases.
MiamiOH OARS

Utilizing Cohort Studies to Address Health Outcomes in Cancer Survivors (UG3/UH3 Clinic... - 0 views

  •  
    Through this Funding Opportunity Announcement (FOA), the NCI invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors. This RFA supports research that requires the creation of a new prospective cohort study of cancer survivors that addresses a gap in knowledge pertaining to the health of cancer survivors. Proposals must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or other understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and include information from the following five domains: 1) disease characteristics (e.g., type, stage), 2) individual survivor characteristics (e.g., comorbidities, SES, social connections, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity) and 5) quality of life outcomes (health related quality of life). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3 Planning-Exploratory Phase focused on recruitment and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 will be proposed by the PI, with approval by NCI, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated so that all aims will be completed in the UH3 phase.
MiamiOH OARS

DoD Prostate Cancer, Health Disparity Research Award - 0 views

  •  
    The FY20 PCRP Health Disparity Research Award supports promising research ideas that have high potential to make a significant impact in eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship. Applications for this award are encouraged to be relevant to one or more of the FY20 PCRP Health Disparity Research Award Focus Areas and must ed to the selected focus area(s). If the proposed project does not address one of the FY20 PCRP Health Disparity Research Award Focus Areas, the application must provide a description to justify how the project will nevertheless address a critical disparity-related need in the field of prostate cancer research and/or patient care. Applications are encouraged from a spectrum of disciplines, including but not limited to basic science, engineering, bioinformatics, population science, psycho-oncology, translational research, health care services
MiamiOH OARS

American Association for Cancer Research Invites Applications for Transformative Cancer... - 0 views

  •  
    In pursuit of that mission, the organization is inviting applications for its AACR NextGen Grants for Transformative Cancer Research program. Through the program, grants of up to $450,000 over three years will be awarded in support of young investigators engaged in creative, paradigm-shifting cancer research that has not be funded through conventional channels. The proposed research must represent a highly innovative approach to a major challenge in cancer and have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science, but at least one AACR NextGen Grant will be awarded to a breast cancer-focused project.
MiamiOH OARS

Pew Charitable Trust 2021 Scholars Program - 0 views

  •  
    Two programs are combined in this competition: the Pew Scholars Program in the Biomedical Sciences and the Pew-Stewart Scholars for Cancer Research Program; both are intended for early-career research with an emphasis on interdisciplinary projects Who should apply: Early-career assistant professors with a research interest in biomedical studies or cancer studies
MiamiOH OARS

Gordon and Betty Moore Foundation Issues RFP for Development of Clinical Quality Measur... - 0 views

  •  
    In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative, which aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes, and save lives. According to the foundation, twelve million Americans experience a diagnostic error each year, with diagnostic errors playing a role in an estimated 40,000 to 80,000 deaths annually in the U.S. In short, there is an urgent need to improve diagnosis; however, without an awareness of baseline performance and standards against which to compare performance, there is no way to measure improvement or to gauge the results of interventions. Despite a lengthy and growing list of clinical quality measures in health care, few existing measures address diagnostic performance specifically. The challenge of finding meaningful clinical measures for diagnosis reflects the complexity of the diagnostic process.
1 - 20 of 849 Next › Last »
Showing 20 items per page